



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/81

August 26, 2025

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - Biocon

Subject: Notification to Stock Exchanges

Dear Sir/Madam,

This is to inform you that Biocon Pharma Limited, a wholly-owned subsidiary of the Company, has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for its ANDA for Sitagliptin Tablets USP, in 25 mg, 50 mg and 100 mg strengths. Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The approval will further strengthen Biocon's portfolio of vertically integrated drug products.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Ekta Agarwal
Interim Company Secretary and Compliance Officer
Membership No.: FCS 11388